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Abstract  23 
 24 
The effect of cerebral vasospasm (CVS) following aneurysmal subarachnoid hemorrhage 25 
(SAH) on critical closing pressure (CrCP) has not been fully delineated. Using cerebral 26 
impedance methodology, we sought to assess the behavior of CrCP during CVS. As CrCP 27 
expresses the sum of intracranial pressure (ICP) and vascular wall tension, we also explored 28 
its role in reflecting changes in vascular tone occurring in small vessels distal to spasm.  29 
 30 
This retrospective analysis was performed using recordings from 52 patients, diagnosed with 31 
CVS through transcranial Doppler measurements. CrCP was calculated non-invasively using 32 
arterial blood pressure and blood flow velocity. Outcome was assessed at both discharge and 33 
3 months after ictus with the Glasgow Outcome Scale. 34 
 35 
The onset of CVS caused significant decreases in CrCP (p=0.025), without any observed 36 
significant changes in ICP (p=0.134). Vasospasm induced asymmetry, with CrCP ipsilateral 37 
to CVS becoming significantly lower than contralateral (p=0.025). Unfavorable outcomes 38 
were associated with a significantly lower CrCP after the onset of CVS (discharge: p=0.014; 39 
3 months post SAH: p=0.020). 40 
 41 
CrCP is reduced in the presence of CVS in both temporal and spatial assessments. As ICP 42 
remained unchanged during CVS, reduced CrCP most probably reflects a lower wall tension 43 
in dilated small vessels distal to spasm. 44 
 45 
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Introduction  48 
Cerebral vasospasm (CVS) is one of the most deleterious complications following 49 
subarachnoid hemorrhage (SAH)
1–3
, being thought to disturb cerebral haemodynamics, 50 
leading often to hypoperfusion
3–5
 and contributing to delayed cerebral ischemia (DCI)
6–8
. 51 
However, the stenosis of the spastic artery alone cannot fully explain the subsequent 52 
development of DCI, as not all patients with CVS, detected either radiologically or with 53 
transcranial Doppler (TCD), develop DCI
8–10
.  54 
For this reason, assessment of changes in the cerebral microvasculature distal to spastic 55 
vessels may be important. However, previous studies have yielded conflicting results. 56 
Positron emission tomography and radioisotope studies have reported findings of maximal 57 
vasodilatation
11,12
 and an impaired vasoreactivity distal to spastic segments
13,14
, whereas 58 
another experimental study reported narrowing of intraparenchymal arterioles post SAH
15
. 59 
Moreover, both TCD and Near Infrared Spectroscopy techniques have demonstrated that an 60 
early onset of dysautoregulation before vasospasm correlates with the occurrence of DCI but 61 
not with a worse outcome
16
, unless autoregulatory failure spreads to both hemispheres.
17
 This 62 
may further complicate our understanding of the microvasculature’s role in SAH.    63 
A parameter that could aid in this situation is critical closing pressure (CrCP), which 64 
estimates the theoretical lowest value of arterial blood pressure (ABP) that is adequate for 65 
maintaining cerebral blood flow
18
. Any value of ABP below this threshold will result in a 66 
collapse of small vessels, leading to cessation of blood flow. CrCP has been modelled as the 67 
sum of intracranial pressure (ICP) and vascular wall tension (WT) of small vessels
19
. 68 
Therefore, observation of how CrCP and WT vary can provide an insight into the dynamics 69 
of cerebral resistive vessels and its behavior in pathological states like CVS.  70 
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The use of CrCP in clinical practice has been restricted by methodological drawbacks, 71 
namely due to presence of difficult to interpret negative CrCP values in conditions with 72 
increased cerebral blood flow velocity
20–23
, including CVS
24
. We have recently described a 73 
method for estimating CrCP based on cerebrovascular impedance
25,26
, which has 74 
demonstrated a good correlation with traditional methods in many clinical conditions
26,27
, 75 
without  yielding negative values. 76 
The primary aim of our study was to describe the behavior of CrCP during CVS. First, 77 
because the state of the microvasculature in SAH is unclear, and with CrCP being related to 78 
vasomotor tone, we examined whether any changes in CrCP presented during CVS could be 79 
indicative of changes in the microvascular wall tension distal to spasm. Secondarily, we 80 
explored the relationship of CrCP with autoregulation and how this relationship becomes 81 
affected with CVS. Finally, we also explored the existence of any association of CrCP and 82 
outcome following SAH. 83 
 84 
Methods 85 
Patients 86 
We  retrospectively analyzed  prospectively collected data from a group of 98 aneurysmal 87 
SAH patients admitted to the Neurocritical Care Unit of Addenbrooke’s Hospital, Cambridge 88 
(June 2010-January 2012)
16,28
. Approval of the study was given by the Addenbrooke’s 89 
Research Ethics Committee. Patients gave written informed approval for the study or in case 90 
they were incapacitated, the written consent was signed from next-of-kin. The guidelines 91 
governing the prospective study on which this retrospective analysis is based on have been 92 
reported previously by Budohoski et al
16
, where the cohort was assessed from the aspect of 93 
early changes in cerebral autoregulation.  94 
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Bilateral TCD measurements at the temporal window (depth of 40-60 mm) were used to 95 
identify CVS in a total of 52 patients [median age: 52 years (interquartile range 45-60); 96 
females/males: 36/16] who had a mean blood flow velocity (FV) in the middle cerebral artery 97 
(MCA) exceeding 120 cm/s, with a concomitant Lindegaard Ratio (LR) of above 3.0 on 98 
TCD
29
. Overall patient characteristics are presented on Table 1 (Section A). The median 99 
onset of CVS was 6 days post SAH. Cerebral perfusion was optimized with the use of 100 
hypertension, hypervolemia, and hemodilution as part of the triple-H therapy in patients who 101 
developed DCI (31/52 of CVS patients)
16,30
. The Glasgow Outcome Scale (GOS) was used 102 
for assessing outcome at both discharge from hospital and 3 months post SAH.  103 
 104 
Monitoring and Data Analysis 105 
Monitoring periods included recordings of ABP, ICP and bilateral FV, performed every 1-2 106 
days
16
. ABP was measured either from the radial artery using a pressure monitoring kit 107 
(Baxter Healthcare, Deerfield, IL, USA), or non-invasively with a Finapres 2300 finger 108 
plethysmograph (Ohmeda, Amsterdam, The Netherlands) zeroed at the heart level in all 109 
patients. Patients were supine with the head of the bed raised 30-45 degrees. Patients 110 
requiring ventriculostomy for hydrocephalus (N=21) had an external ventricular drain (EVD), 111 
which was used for drainage of cerebrospinal fluid when open and for ICP measurements 112 
when closed. The external drainage was closed during the TCD monitoring period, 113 
preventing possible interference of high cerebrospinal compliance (open EVD) with cerebral 114 
hemodynamics. Out of these 21 patients, 14 had a full set of measurements both before and 115 
during CVS that were used for analysis of change in ICP during CVS. Doppler monitoring of 116 
FV was performed bilaterally at MCAs, with the use of a DopplerBox (DWL Compumedics, 117 
Singen, Germany) and a head positioning device (Lam Rack, DWL Compumedics) via the 118 
temporal window at a depth of 45-60 mm. The raw data signals were recorded at sampling 119 
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frequency of 200 Hz using ICM+ software (Cambridge Enterprise, Cambridge, UK, 120 
http://www.neurosurg.cam.ac.uk/icmplus/). Mean values of signals were calculated in ICM+ 121 
by averaging values in a 10-second time window and then secondarily averaging them over 122 
whole monitoring time (20-40 min). Heart rate was calculated using spectral position of the 123 
peak associated with the first harmonic of ABP.  124 
Cerebral autoregulation was assessed with a TCD-derived autoregulation index, Sxa, 125 
calculated as a moving correlation coefficient between ABP and systolic FV, from a 300-126 
second window with averaging every 10 seconds
16
. 127 
 128 
Estimation of Critical Closing Pressure 129 
CrCP was estimated with the impedance methodology
25,26
, using a non-invasive version 130 
requiring signals of ABP and TCD FV
31
: 131 
]
1)2(
1
1[
2 

HRCaCVR
ABPCrCP  132 
CVR stands for cerebrovascular resistance with Ca representing arterial compliance of the 133 
cerebral bed. Calculation of CVR and Ca can be perfomed with algorithms based on 134 
measurements of FV and ABP, presented in previous studies
32,33
. HR represents heart rate 135 
(beats/s). 136 
Please see the Appendix for further details regarding non-invasive CrCP methodology.  137 
 138 
Statistical analysis 139 
The IBM SPSS Statistics 20 package (Armonk, NY, USA) was used for the statistical 140 
analysis. The Shapiro–Wilk test was used to confirm normal distribution of the samples. 141 
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Results are presented in a mean value ± standard deviation (SD) format. Bivariate 142 
correlations were used, with R being the Pearson correlation coefficient. The level of 143 
significance (p-value) was set at 0.05. 144 
For analysis of CrCP in cases of unilateral CVS, the TCD recordings from the side ipsilateral 145 
to CVS were used, whereas when bilateral CVS was present, the analysis included averaging 146 
of both sides. 147 
Temporal and spatial comparisons were used to assess how CrCP was affected by the 148 
presence of CVS, performed with paired samples T-tests. In temporal comparison, the cohort 149 
of CVS patients was dichotomized in time, with comparison of averaged periods before and 150 
during CVS, based on the TCD onset of CVS for each patient. Spatial analysis included 151 
bilateral comparisons (ipsilateral-contralateral to CVS). Both temporal and spatial 152 
comparisons were made using data of patients with recordings both before and during CVS 153 
(37 patients out of the total 52; Figure 1). 154 
Autoregulation analysis included averaged periods of calculated autoregulatory index Sxa, 155 
before and during CVS, with the relationship to CrCP being explored through correlation to 156 
the respective averaged periods of CrCP.  157 
Outcome analysis consisted of comparisons between favorable (GOS: good recovery, 158 
moderate disability) vs unfavorable (GOS: severe disability, vegetative state, death) 159 
outcomes, for the patients who had recordings both before and during CVS (N=37). 160 
Comparisons included then averaged recordings of CrCP and FV for several days both before 161 
and after the CVS onset. The outcome scores were collected at discharge and at 3 months 162 
after injury. Binary logistic regression models were used for analysing the association of 163 
CrCP to outcome. Section B of Table 1 presents a comparison between patients of favorable 164 
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and unfavorable outcomes, with the latter presenting a significantly worse WFNS score and a 165 
higher percentage of occurrences of hydrocephalus and DCI.  166 
The rest of SAH cohort that did not develop CVS (46 out of 98 patients) was used as a 167 
control group, where CrCP was averaged for the whole monitoring period.  168 
 169 
Results 170 
Effects of vasospasm on critical closing pressure 171 
Mean values of measured parameters and CrCP before and during CVS are presented in 172 
Table 2. CrCP became significantly lower during CVS, decreasing by 14.7% after the onset 173 
of CVS (p=0.025). FV was significantly increased during CVS (p<0.001), as was ABP 174 
(p<0.001).  175 
ICP did not significantly change during CVS, even though a tendency to decrease was 176 
observed after the onset of CVS (before CVS: 13.55 ± 4.04 mm Hg; after onset of CVS: 177 
11.04 ± 5.78 mm Hg; p=0.134, N=14). Changes in ICP were not correlated to changes in 178 
CrCP from before to during vasospasm (absolute changes; p=0.379, N=14). 179 
Changes in CrCP observed in time after SAH were not associated with changes in FV, as the 180 
absolute difference of CrCP before and during CVS was not correlated with the respective 181 
absolute difference of FV (R=-0.227; p=0.177). The independence of CrCP and FV was 182 
further confirmed with an overall absence of correlation between them during CVS 183 
(p=0.148). 184 
No significant interhemispheric difference could be found in either CrCP or FV before the 185 
onset of CVS (p=0.394 and p=0.143 respectively). However, the presence of CVS reduced 186 
CrCP in both hemispheres and induced asymmetry, with CrCP ipsilateral to CVS becoming 187 
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significantly lower than contralateral CrCP during to CVS (p=0.025; Figure 2). Ipsilateral FV 188 
was significantly higher than contralateral FV during CVS (154.13 ± 44.94 vs 104.45 ± 40.58 189 
cm/s; p<0.001).  190 
Interhemispheric changes in CrCP were not correlated to changes in FV during CVS 191 
(R=0.056; p=0.763). The interhemispheric asymmetry of CrCP was not constant across the 192 
days post SAH, with the biggest differences being on days 11 and 12 (Table 3). 193 
Comparison of CrCP values of CVS patients to a control group, consisting of the rest 46 SAH 194 
patients (out of a total 98) that did not develop CVS, demonstrated a significantly lower CrCP 195 
in CVS cases (CrCP after the onset of vasospasm in CVS patients: 40.70 ± 16.72 mm Hg; 196 
CrCP in SAH patients without no presence of vasospasm: 34.67 ± 9.77 mm Hg; p=0.015). No 197 
significant difference could be found between the control SAH group and the averaged period 198 
before the presence of vasospasm for the CVS patients (p=0.659).  199 
 200 
Autoregulation 201 
Sxa and CrCP were inversely correlated before CVS (R=-0.329; p=0.043). Autoregulation 202 
presented signs of impairment during CVS, as shown by a significantly increased Sxa (from 203 
0.14 ± 0.18 to 0.22 ± 0.15; p=0.023). During CVS, there was no correlation between Sxa and 204 
CrCP (R=0.122; p=0.471).   205 
 206 
Outcome  207 
Compared to patients with favorable outcome (N=29), unfavorable cases (N=8) had a 208 
significantly lower CrCP during the CVS period, with outcome assessed both at discharge 209 
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(p=0.014, Figure 3A) and at 3 months post SAH (p=0.020, Figure 3B). No association was 210 
found between CrCP before CVS onset and outcome (p>0.05 for all).  211 
Adjusting for FV during CVS, binary logistic analysis (with independent parameters CrCP 212 
and FV) indicated a lower CrCP to remain significantly and independently to FV associated 213 
with unfavorable outcome (Table 4).  214 
 215 
Discussion 216 
Overall, during cerebral vasospasm we observe significant decrease in CrCP. This could be 217 
seen both in temporal assessment where the onset of CVS resulted in a decrement of CrCP, 218 
and in spatial investigation, where CVS caused an interhemispheric CrCP difference, with a 219 
lower CrCP ipsilateral to spasm. This could be also seen when comparing to a control group 220 
of SAH patients without presence of CVS: whereas before the onset of CVS there was no 221 
difference between patients that later developed CVS and the control group, after the onset of 222 
CVS, CrCP became significantly lower in comparison to the control group.  223 
Because CrCP is the sum of ICP and WT
19
, any observed changes could be the end result of 224 
alterations in either variable. The onset of CVS did not cause any significant changes in ICP, 225 
which remained at relatively low levels. Therefore, the observed changes in CrCP could be 226 
reflecting changes in WT, where a reduced WT would be signifying a reduced vasomotor 227 
tone and dilated vessels. This preliminary inference would be in agreement with previous 228 
studies demonstrating dilated parenchymal small arteries and arterioles in the low perfusion 229 
area distal to spasm
11–14,34
, attributed to a possible autoregulatory response
35,36
.  230 
The behavior of the microvasculature during CVS has previously attracted considerable 231 
interest, although both clinical and experimental studies have produced conflicting results
11–
232 
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15
. A better understanding of microcirculatory changes may lead to better ways of 233 
maintaining adequate local perfusion pressure, which otherwise gets significantly affected by 234 
the stenosis
3–5
. Lowering of CrCP during spasm for most investigators is counterintuitive; 235 
spasm increases tension of conductive vessels, therefore CrCP should rather rise than 236 
decrease. But CrCP describes better the state of resistive arterioles rather than conductive 237 
vessels
19
. Spasm in conductive vessels decreases effective cerebral perfusion pressure at the 238 
level of the resistive arterioles, causing dilation, a decrease in wall tension, and decreases in 239 
CrCP.  240 
 241 
Clinical significance   242 
The changes in CrCP occurred despite the initiation of triple-H therapy, which includes 243 
raising of ABP
30
. Normally, arterial hypertension causes vasoconstriction
35,37
, which is 244 
known to lead to a higher CrCP through an increased WT
26
. Therefore, the observed 245 
decreases in CrCP could signify a strong dilatatory effect of proximal vasospasm on distal 246 
microcirculation.   247 
A lower CrCP after the onset of CVS was associated with an unfavorable outcome, in 248 
contrast to FV. As the level of FV is of high importance in TCD-assessed vasospasm
23,29,36
, 249 
this preliminary finding denoting the relationship of CrCP with FV and outcome deserves 250 
further discussion. With CrCP appearing to express changes in microcirculation, this finding 251 
could enhance its clinical importance, potentially denoting its role as a quantitative surrogate 252 
marker of dilated vessels being associated with a worse outcome.  253 
Furthermore, before the CVS onset an inverse association was found between CrCP and 254 
autoregulation: a lower CrCP being linked with a higher Sxa or worsening of autoregulation. 255 
This relationship could be explained by an apparent reduced pressure reactivity due to vessels 256 
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becoming dilated and therefore having a lower vasomotor tone, expressed with a reduced 257 
CrCP. A similar  relationship between WT and autoregulation has been previously observed 258 
in traumatic brain injury
38
.  259 
Advantages of impedance-based CrCP 260 
The main advantage of impedance CrCP is that its renderings in SAH patients agreed with 261 
the findings of an earlier study using two traditional CrCP methods
24
, without presenting 262 
though any negative values for this pathology, as has been also verified with this estimation 263 
method in both experimental and clinical scenarios.
26,27,31,38
.  264 
Despite CrCP calculations being based on FV-derived information, the changes in CrCP 265 
during CVS were independent from changes in FV, therefore not being artificially driven by 266 
increasing FV
24
 but rather being representative of changes in the physiology of the 267 
microvasculature. Most importantly the calculations with our method were not affected by 268 
the diameter change of the insonated vessel, as the calculation of CrCP is independent of the 269 
insonated vessel’s unknown cross-sectional area (please see Appendix)26,33.  270 
All of the above makes the new impedance based measures of CrCP superior to the 271 
traditional methods and suitable for use in clinical practice, particularly in SAH patients 272 
where vasospasm has occurred. 273 
 274 
Limitations 275 
Calibration of ABP at heart-level instead of brain-level could be considered a confounding 276 
factor in this study, leading to an overestimation of ABP at the level of the insonated vessel
39
, 277 
potentially affecting therefore impedance CrCP calculations. However, this study explored 278 
the changes in CrCP caused by the presence of vasospasm, rather than assessing absolute 279 
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values of CrCP. Therefore the use of this ABP calibration, consistent throughout the 280 
measurements with patients having an unchanged 30-45 degrees head up, could be 281 
considered as adequate for the purposes of this study.  282 
In contrast to continuous ABP measurements, TCD recordings were performed for short 283 
periods (30 to 60 minutes) for every patient on a day-to-day basis
16
. This means that 284 
calculation of CrCP was only possible when the recordings of ABP and FV were combined 285 
during these short periods. This is a known limitation of the TCD methodology at present, 286 
and one that can only be overcome by the advent of new self-focusing TCD probes. 287 
Nevertheless, these ‘snapshots’ of CrCP were deemed adequate for the aims of the study16. 288 
The overall number of patients may pose a limitation for this study. However, despite the 289 
small number of patients, the results were able to: a) present an agreement with the results of 290 
a past study
24
 b) demonstrate at the same instance the strength of the reliable impedance 291 
CrCP method and c) preliminary indicate an association of CrCP with a worse outcome, 292 
independently to FV, which consists of a widely used marker of CVS. Furthermore, the lack 293 
of a multivariate regression model for outcome assessment is a limitation for this study. A 294 
prospective study with a larger number of patients will be able to further explore the 295 
relationship of CrCP with outcome, through a multivariate regression analysis taking under 296 
consideration other parameters such as age, sex, WFNS score etc. With a larger sample of 297 
SAH patients a further analysis could investigate whether a specific threshold for CrCP 298 
predicting a worse outcome could be identified.   299 
Furthermore, the small number of patients with ICP measurements for assessing changes 300 
occurred during CVS could be considered as a limitation, mainly attributed to the fact that 301 
SAH patients do not routinely receive intracranial monitoring
16
. However, similar findings 302 
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regarding the effect of CVS on ICP have been presented before, therefore confirming our 303 
results.
24
 304 
 305 
Conclusions 306 
The presence of vasospasm significantly reduced CrCP, as seen in temporal assessment 307 
where the onset of vasospasm resulted in a decrement of CrCP, and in spatial assessment, 308 
where vasospasm caused an interhemispheric CrCP difference, with a lower CrCP ipsilateral 309 
to spasm.  310 
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Titles and legends to figures 487 
Figure 1: Dichotomization of patients into study groups, considering the aims of each 488 
comparison and the availability of monitored signals. From a cohort of 98 patients with 489 
subarachnoid hemorrhage (SAH), patients that developed cerebral vasospasm (CVS) were 490 
studied (52). From this group, the intracranial pressure (ICP) part consisted of a total of 21 491 
patients with monitoring of ICP. Out of these 21 patients, 14 had ICP measurements both 492 
before and during CVS and were used for assessing changes in ICP following the onset of 493 
CVS. For the CrCP part, 37 patients were used for CrCP comparisons, after fulfilling the 494 
criteria of full measurements, regarding presence of arterial blood pressure (ABP) and 495 
bilateral transcranial Doppler flow velocity (FV) both before and during CVS.   496 
Figure 2: Bilateral comparison of critical closing pressure (CrCP) for periods before and 497 
during vasospasm (CVS): CVS causes asymmetry with ipsilateral CrCP becoming 498 
significantly lower than contralateral, whereas in contrast, no significant interhemispheric 499 
difference was found before CVS. Error bars represent +/- 2 standard errors. 500 
Figure 3: Association of critical closing pressure (CrCP) after the onset of vasospasm (CVS) 501 
with outcome of patients (N=37) at both discharge (A) and 3 months post subarachnoid 502 
hemorrhage (SAH) (B). In both time points, unfavorable outcome cases presented a 503 
significantly lower CrCP, in comparison to favorable cases. Error bars represent +/- 2 504 
standard errors. 505 
 506 
 507 
 508 
 509 
 510 
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Tables 511 
 512 
Table 1 Characteristics of patients with cerebral vasospasm, consisting of a subgroup of the 513 
total cohort of patients with subarachnoid hemorrhage. Section A presents overall 514 
characteristics, with Section B comparing characteristics of patients with favorable and 515 
unfavorable outcomes.  516 
 517 
Section Variable Value 
 
 
 
 
 
A 
Number of Patients, n 52 
Age, median years (IQR) 52 (45-60) 
Sex, female/male 36/16 
WFNS grade, median Modified Fisher grade, 
median 
1, n 16 1, n 9 
2, n 16 2, n 6 
3, n 2 3, n 29 
4, n 12 4, n 8 
5, n 6 - 
Aneurysm location, n 
ACA 2 MCA 11 
AChA 3 PComA 16 
AComA 14 PCA 0 
BA 1 PICA 1 
ICA 3 VBJ 0 
Clipping/coiling, n 39/17 Re-bleeding, n 0 
Surgical Infarcts, 
n 
8 Hydrocephalus, 
n 
28 
21 
 
 
 
 
 
 
 
B 
Outcome (N=37 patients) 
median GOS at 3 months  5 (IQR: 4-5) 
Favorable vs. Unfavorable  
Parameter Favorable Unfavorable p-value 
Number of 
patients, n 
29 8 - 
Age, median 
years (IQR) 
54 (45-62) 53 (49-63) 0.732 
Sex, 
female/male 
21/8 4/4 - 
WFNS grade, 
median 
2  4 0.003* 
Modified 
Fisher grade, 
median 
3 2 0.332 
Hydrocephalus 16 6 - 
DCI 15 6 - 
Abbreviations: ACA: anterior cerebral artery; AChA: anterior choroidal artery; AComA: 518 
anterior communicating artery; BA: basilar artery; ICA: internal carotid artery; IQR: 519 
interquartile range; MCA: middle cerebral artery; PCA: posterior cerebral artery; PComA: 520 
posterior communicating artery; PICA: posterior inferior cerebellar artery; VBJ: 521 
Vertebrobasilar junction; WFNS: scale of World Federation of Neurosurgical Societies 522 
GOS: Glasgow Outcome Scale; *: significant difference – independent samples test. 523 
 524 
 525 
 526 
 527 
 528 
 529 
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Table 2 Comparison of mean values and standard deviations (mean ± SD) of parameters 530 
before and during cerebral vasospasm (Paired Samples T-test) 531 
 532 
N=37 Before CVS During CVS p-value 
CrCP [mm Hg] 40.70 ± 16.72 34.71 ± 9.85 P=0.025 
FV [cm/s] 80.38 ± 24.21 153.41 ± 42.99 P<0.001 
ABP [mm Hg] 90.33 ± 14.64 103.39 ± 18.78 P<0.001 
 533 
Abbreviations: CVS, cerebral vasospasm, CrCP, critical closing pressure; FV, blood flow 534 
velocity; ABP, arterial blood pressure. Both CrCP and FV parameters refer to ipsilateral to 535 
CVS measurements 536 
 537 
 538 
 539 
 540 
 541 
 542 
 543 
 544 
 545 
 546 
 547 
 548 
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Table 3 Interhemispheric difference in CrCP, patient-averaged by day post-SAH from the 549 
onset of spasm and onwards (median onset for all patients: 6 days post SAH). Based on 550 
clinical assessment, the monitoring time was not equivalent for all patients, therefore the 551 
number of available patients analyzed for each day is denoted.   552 
 553 
Days  
post SAH 
Number  
of Patients 
ΔCrCP  
[mean±SD; mm Hg] 
6 median onset of spasm 
7 20 0.66±5.79 
8 21 3.24±7.37 
9 24 2.79±5.68 
10 20 1.62±8.69 
11 12 6.87±5.27 
12 11 5.14±6.77 
13 10 1.75±6.60 
 554 
Abbreviations: CrCP, critical closing pressure; ΔCrCP, interhemispheric differences in 555 
CrCP; SAH, subarachnoid hemorrhage  556 
 557 
 558 
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Table 4: Binary Logistic Regression Model for predicting outcome. 559 
 560 
 
Outcome 
(Favorable vs Unfavorable) 
 
Parameters 
B  
(standard 
Error) 
 
Wald 
 
p 
 
OR 
95% CI for 
OR 
 
Discharge 
CrCP 0.099  
(0.045) 
4.82 0.028 1.105 1.011-1.207 
FV -0.010 
(0.008) 
1.702 0.192 0.990 0.974-1.005 
 
3 months 
CrCP 0.104 
(0.052) 
3.991 0.046 1.110 1.002-1.229 
FV -0.011 
(0.009) 
1.524 0.217 0.989 0.972-1.007 
 561 
Abbreviations: CrCP, critical closing pressure; FV, flow velocity; OR, odds ratio; CI, 562 
confidence interval. 563 
 564 
 565 
 566 
 567 
 568 
 569 
 570 
 571 
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Appendix  573 
 574 
Calculation of non-invasive CrCP 575 
 576 
The basis of non-invasive CrCP is a multi-parameter invasive model, derived from the 577 
concept of impedance
25,26
: 578 
 579 
1)2( 2 

HRCaCVRi
CPP
ABPCrCP
  
(1) 580 
 581 
The invasive parts requiring ICP measurements are CPP (calculated as ABP-ICP) and 582 
cerebrovascular resistance (CVRi), approximated as
40
:  583 
 584 
       585 
 586 
The parameter Sa in the denominator represents the unknown cross-sectional area of the 587 
insonated vessel.  588 
Ca can be estimated as
32,33
:  589 
 590 
       591 
 592 
A1: fundamental harmonic amplitude of ABP; CaBV1: amplitude of the fundamental 593 
harmonic of cerebral arterial blood volume (CaBV), derived by using a 10-second discrete 594 
Fourier transformation of CaBV’s time series. CaBV is approximated by integrating FV pulse 595 
waveform with the beat-to-beat mean removed
32,33
. 596 
26 
 
The product of Ca and CVRi in eq. (1) cancels out the parameter Sa, as has been described in 597 
the impedance methodology
26
. 598 
Approximating CrCP non-invasively, we used the CrCP formula, substituting CPP with ABP, 599 
with CVRi being now approximated non-invasively as
40
: 600 
 601 
       602 
 603 
With these substitutions, the non-invasive model of impedance CrCP is now rendered as
31
: 604 
]
1)2(
1
1[
2 

HRCaCVR
ABPCrCP
       
           (2) 605 
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